Department of Translational Medicine (DiMET), University of Eastern Piedmont, Via Solaroli 17, 28100, Novara, Italy.
Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy.
Arch Virol. 2022 Aug;167(8):1669-1674. doi: 10.1007/s00705-022-05466-y. Epub 2022 May 22.
The aim of this study was to evaluate plasmatic and urinary therapeutic drug monitoring (TDM) of tenofovir disoproxil fumarate (TDF) in a cohort of patients with chronic hepatitis B (CHB). In 68 enrolled patients, the estimated glomerular filtration rate (eGFR) was 68 mL/min in naive subjects, while in adefovir dipivoxil (ADV)-pretreated patients, it was 55.5 mL/min (p < 0.001). The HBV E genotype was associated with lower TDF levels (β = -0.698, p < 0.001). The urinary TDF concentration was associated with ADV pretreatment (β = 0.829, p < 0.001). Determination of urinary concentrations of TDF may be useful in the clinical management of older CHB patients and those with previous treatment with ADV.
本研究旨在评估慢性乙型肝炎（CHB）患者中替诺福韦二吡呋酯（TDF）的血浆和尿液治疗药物监测（TDM）。在 68 名入组患者中，初治患者的估算肾小球滤过率（eGFR）为 68mL/min，而阿德福韦酯（ADV）预处理患者的 eGFR 为 55.5mL/min（p<0.001）。HBV E 基因型与 TDF 水平较低相关（β=-0.698，p<0.001）。尿 TDF 浓度与 ADV 预处理相关（β=0.829，p<0.001）。测定 TDF 的尿浓度可能有助于对老年 CHB 患者和有 ADV 治疗史的患者进行临床管理。
